Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease

Gastroenterol Hepatol. 2023 Oct;46(8):631-632. doi: 10.1016/j.gastrohep.2022.10.016. Epub 2022 Nov 7.

[Article in English, Spanish]

Authors

Francisco Ángel Lao Domínguez¹, María José Fobelo Lozano², Antonio Gutiérrez Pizarraya², Manuel Castro Fernández³

Affiliations

¹ Hospital Universitario Virgen de Valme, Pharmacy Service, Seville, Spain. Electronic address: fralaodom@gmail.com.
² Hospital Universitario Virgen de Valme, Pharmacy Service, Seville, Spain.
³ Hospital Universitario Virgen de Valme, Digestive Medicine Service, Seville, Spain.

PMID: 36356717
DOI: 10.1016/j.gastrohep.2022.10.016

No abstract available

Publication types

Case Reports

MeSH terms

Crohn Disease* / drug therapy
Humans
Patients
Remission Induction
Treatment Outcome
Ustekinumab* / therapeutic use

Substances

Ustekinumab